ArticleFrontiers in cardiovascular medicine2026
Mortality in patients undergoing catheter-based therapy vs. anticoagulation alone for intermediate-high risk pulmonary embolism.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary embolism is a common and potentially fatal medical condition. Current guidelines recommend therapeutic anticoagulation for intermediate-high risk pulmonary embolism as a first-line strategy. However, it is unclear whether these patients may benefit from interventional treatments, such as catheter-based thrombectomy or catheter-based thrombolysis, compared to anticoagulation alone regarding mortality. Our aim was to gain insight into optimal treatment strategies of intermediate-high risk PE patients and to evaluate outcomes of different management strategies with regard to all-cause mortality. Methods: We retrospectively evaluated a total of 236 patients, 133 patients undergoing catheter-based thrombectomy or catheter-based thrombolysis (interventional group) and 103 patients receiving anticoagulation alone (conservative group) at our institution between 2003 and 2024. All patients were classified as intermediate-high risk. The primary endpoint was all-cause mortality. Results: The overall mortality for all patients with intermediate-high risk pulmonary embolism was 12.0% at 12 months. Depending on the treatment approach, all-cause mortality after 12 months occurred in 14 of 103 patients (14.0%) in the conservative group and in 14 of 133 patients (11.0%) in the interventional group which did not significantly differ ( Discussion: In patients with acute intermediate-high risk pulmonary embolism catheter-based treatment did not show a significant reduction in mortality within 12 months compared to anticoagulation alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.